Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 May 25.
Published in final edited form as: Cytometry A. 2016 Feb 9;89(5):427–429. doi: 10.1002/cyto.a.22808

OMIP-026: Immunologic Checkpoint Expression on Murine Effector and Memory T-cell Subsets*

Satoshi Nemoto 1, Adam W Mailloux 1, Jodi Kroeger 2, James J Mulé 1
PMCID: PMC4879048  NIHMSID: NIHMS782580  PMID: 26859685

Purpose and Appropriate Sample Types

This panel was designed to assess the expression levels of cell surface inhibitory receptors known as “immune checkpoints” within the context of multiple naïve, activated, memory, and effector phenotypes among T-cells for subsequent adoptive transfer using the CD45.1/CD45.2 congenic system in C57BL/6 mice. It can be easily adapted to other congenic systems, or may be used without any congenic marker. While many panels have been published that analyze T-cell activation, memory phenotypes, or effector differentiation states, few, if any, are comprehensive enough to asses these compartments simultaneously while measuring inhibitory immune checkpoint receptor expression. The ability to do so within a congenic system creates a powerful tool for investigating the evolution of T-cell based immune responses in a broad range of contexts. Here, the panel is used to analyze the T-cell compartment in normal spleen, or T-cells infiltrating subcutaneous murine colon adenocarcinoma, MC38. However, any murine source of T-cells would serve as an appropriate sample source for this panel.

Background

Upon activation, T-cells undergo a high rate of proliferation, and alter the expression of numerous genes associated with effector response, or with supportive function. This is followed by a contraction period in which the majority of activated T-cells die off and a remaining minority of antigen-specific T-cells transition into one of multiple longer-lived memory T-cell phenotypes capable of future reactivation in the event of antigen re-encounter. Concomitant with T-cell activation and subsequent memory formation, are alterations in cell surface protein expression that can be used to classify T-cell subsets and identify their activation or memory state. This panel is built upon a basic framework that allows for a comprehensive overview of these subpopulations. It includes CD69, which is a traditional marker for T-cell activation that is one of the earliest inducible proteins on the cell surface following activation of both helper T-cells (TH), and cytotoxic T-cells (TC), which can be identified using CD3 and CD4, or CD3 and CD8 respectively. Following activation, T-cells down-regulate CD45RA and up-regulate other higher molecular weight CD45 isoforms (1). While several cases of CD45RA re-expression have been reported on chronically stimulated T-cells (2,3), CD45RA is generally considered a naïve T-cell marker. As T-cells transition into memory phenotypes, the expression of CD44 increases from low to high. Thus, naïve and memory T helper (TH) and T cytotoxic (TC) cells can be identified by discriminating CD44low and CD45high populations and by CD45RA+ and CD45RA populations.

The two major subtypes of memory T-cells, central memory (CM) and effector memory (EM), have been conventionally defined by differential expression of CD62L and CD27. While a number of cell surface molecules have been reported to discriminate these memory subpopulations, it is also appreciated that a degree of plasticity exists between CM and EM T-cells resulting in incomplete overlap among CM/EM markers. This is particularly true among TH cells (4). Therefore, the use of multiple EM/CM markers increases the power to effectively resolve these populations or identify transitional phenotypes. In this panel, CM can be identified as CD62L+ and/or CD27+ cells, while EM can be identified as CD62L and/or CD27.

How it is determined which activated effector T-cells die off during contraction, and which go on to persist as memory T-cells has been an outstanding question in immunology. Recent work has identified two subsets of effector T-cells that can be identified by CD127 and KLRG1 that are associated heightened cytotoxic function and subsequent die off or pre-destination for memory formation. Activated T-cells undergo a transient down-regulation of both KLRG1 and CD127. This brief state is followed by up-regulation of either CD127 or KLRG1. Short-lived effector cells (SLECs) express lower levels of CD127 and heightened levels of KLRG1 while memory precursor cells (MPEC) express higher levels of CD127 and lower levels of KLRG1(5,6).

Finally, this panel also measures the levels of inhibitory receptors recently defined as immunological “checkpoint,” due to the transient nature of their expression following activation, and their potent inhibitory potential upon interaction with cognate ligands (712). Included in this panel are the inhibitory checkpoint receptors TIM3, LAG-3, PD-1, and CTLA-4. To demonstrate how overall naïve, activated, memory, and effector phenotypes can change, labeled infiltrating T-cells from a single cell suspension of resected orthotropic MC38 tumor grown in C57BL/6 mice are overlaid on labeled T-cells from normal murine C57BL/6 spleen (Figure 1).

Figure 1.

Figure 1

Example gating schema. (A) Single cells were gated using forward scatter height versus width parameters followed by side scatter height versus width parameters. Lymphocytes were then gated using forward scatter area versus side scatter area, followed by viability gating using DAPI. TH and TC cells were then selected by gating on CD45.2+CD3+ cells followed by gating on CD4+ or CD8+ cells. Black arrows = gated cells. (B) Early activation and differentiation states can be analyzed using KLRG1 versus CD127 to define SLEC and MPEC populations and CD69 can be used to demark currently activated T-cells. T-cells from healthy C57BL/6 spleen are shown in red, and MC-38 tumor-infiltrating T-cells are overlaid in blue to demonstrate changes in phenotype and differentiation state that may be observed in this panel. Green arrows = gated CD8+ T-cells, orange arrows = gated CD4+ cells. (C) Conventional memory phenotypes including naïve (N), central memory (CM), effector memory (EM), and effector T-cells can be analyzed using a combination of CD44 or CD45RA versus CD27 or CD62L staining. (D) Four immune checkpoint markers may also be analyzed using this panel: PD-1, LAG-3, TIM3, and CTLA-4. Gate percentages in overlaid plots represent analysis from MC-38 tumor-infiltrating T-cell samples. Gates were placed according to fluorescence-minus-one (FMO) controls.

Supplementary Material

Supplemental Material

Table 1.

Summary Table for Application of OMIP-026

Purpose Checkpoint expression on subsets of memory T-cells
Species Mouse
Cell Types Any source containing murine T-cells
Cross-References No similar OMIPs

Table 2.

Reagents for OMIP-026

Specificity Clone Fluorochrome Purpose
CD3 145-2C11 BUV 395 T-cell
CD4 GK1.5 BUV 805 TH
CD8 53-6.7 Alexa Fluor 700 TC
CD69 H1.2F3 PE-CF594 Activation
CD44 IM7 Alexa Fluor 488 Memory
CD45RA 14.8 BV 786 Memory
CD27 LG.3A10 BV 510 Memory
CD62L MEL-14 PE-Cy7 Memory
KLRG1 2F1/KLRG1 PerCP-Cy5.5 Differentiation
CD127 SB/199 BUV 737 Differentiation
PD-1 J43 BV 605 Checkpoint
CTLA4 UC10-4B9 PE Checkpoint
TIM-3 B8.2C12 APC Checkpoint
LAG-3 C9B7W BV 711 Checkpoint
CD45.2 104 APC-Cy7 Congenic
DAPI - DAPI Viability

BUV, Brilliant Ultra Violet™; PE, R-phycoerythrin; BV, Brilliant Violet™; Cy, cyanine; PerCP-Cy5.5, Peridinin-chlorophyll Cy-5.5; APC, allophycocyanin; DAPI 4',6-diamidino-2-phenylindole; TH, T helper cell; TC, T cytotoxic cell.

Footnotes

*

This work was supported by the NCI–NIH (1 R01 CA148995-01; P30CA076292; P50CA168536), the V Foundation, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and the Chris Sullivan Foundation.

Cited References

  • 1.Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35:651–60. doi: 10.1097/CJI.0b013e31827806e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R, Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, et al. Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+CD45RA+CD27+ T cells: the potential involvement of interleukin-7 in this process. Immunology. 2011;132:326–39. doi: 10.1111/j.1365-2567.2010.03386.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Pilling D, Akbar AN, Bacon PA, Salmon M. CD4+ CD45RA+ T cells from adults respond to recall antigens after CD28 ligation. Int Immunol. 1996;8:1737–42. doi: 10.1093/intimm/8.11.1737. [DOI] [PubMed] [Google Scholar]
  • 4.Krawczyk CM, Shen H, Pearce EJ. Functional plasticity in memory T helper cell responses. J Immunol. 2007;178:4080–8. doi: 10.4049/jimmunol.178.7.4080. [DOI] [PubMed] [Google Scholar]
  • 5.Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27:281–95. doi: 10.1016/j.immuni.2007.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kaech SM, Tan JT, Wherry J, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191–8. doi: 10.1038/ni1009. [DOI] [PubMed] [Google Scholar]
  • 7.Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634–43. doi: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 8.Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007;117:3383–92. doi: 10.1172/JCI31184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–8. doi: 10.1038/85330. [DOI] [PubMed] [Google Scholar]
  • 10.Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71:3540–51. doi: 10.1158/0008-5472.CAN-11-0096. [DOI] [PubMed] [Google Scholar]
  • 11.Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 1997;57:4036–41. [PubMed] [Google Scholar]
  • 12.Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–52. doi: 10.1038/ni1271. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material

RESOURCES